Literature DB >> 18607388

CD45 glycosylation controls T-cell life and death.

L A Earl1, L G Baum.   

Abstract

CD45, an abundant and highly glycosylated cell-surface protein, is a critical regulator of T-cell development. CD45 is differentially glycosylated throughout the life of a T cell, and the glycosylation state of CD45 controls recognition by various binding partners, affects intracellular signaling by the cytoplasmic tyrosine phosphatase domain and modulates the response of the T cell to antigen. Although the importance of CD45 during T-cell development has been established, it is becoming increasingly clear that glycosylation of CD45 is a dynamic process that modifies T-cell survival, activation and immune function. In this review, we address changes that occur in CD45 glycosylation during T-cell development and differentiation, describe carbohydrate-binding proteins that recognize differentially glycosylated forms of CD45, and discuss how differential glycosylation alters the T-cell response to a variety of signals involved in selection, activation and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607388     DOI: 10.1038/icb.2008.46

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  27 in total

Review 1.  T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival.

Authors:  Mary C Clark; Linda G Baum
Journal:  Ann N Y Acad Sci       Date:  2012-01-30       Impact factor: 5.691

2.  Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles.

Authors:  Matthias T Stephan; Sirkka B Stephan; Peter Bak; Jianzhu Chen; Darrell J Irvine
Journal:  Biomaterials       Date:  2012-05-15       Impact factor: 12.479

3.  Application of WGA lectin staining for visualization of the connective tissue in skeletal muscle, bone, and ligament/tendon studies.

Authors:  Tatiana Y Kostrominova
Journal:  Microsc Res Tech       Date:  2011-01       Impact factor: 2.769

4.  Impaired Glycoprotein VI-Mediated Signaling and Platelet Functional Responses in CD45 Knockout Mice.

Authors:  Vaishali V Inamdar; John C Kostyak; Rachit Badolia; Carol A Dangelmaier; Bhanu Kanth Manne; Akruti Patel; Soochong Kim; Satya P Kunapuli
Journal:  Thromb Haemost       Date:  2019-06-21       Impact factor: 5.249

5.  Identification of glycoproteins targeted by Trypanosoma cruzi trans-sialidase, a virulence factor that disturbs lymphocyte glycosylation.

Authors:  Romina P Muiá; Hai Yu; Jennifer A Prescher; Ulf Hellman; Xi Chen; Carolyn R Bertozzi; Oscar Campetella
Journal:  Glycobiology       Date:  2010-03-30       Impact factor: 4.313

6.  Prognostic value of CD45 transcriptional expression in head and neck cancer.

Authors:  Mercedes Camacho; Adriana Agüero; Anna Sumarroca; Laura López; Miguel-Ángel Pavón; Francesc-Xavier Avilés-Jurado; Jacinto García; Miquel Quer; Xavier León
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-11-25       Impact factor: 2.503

Review 7.  CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells.

Authors:  Michelle L Hermiston; Julie Zikherman; Jing W Zhu
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  Characterization of a Novel Gene in the Extended MHC Region of Mouse, NG29/Cd320, a Homolog of the Human CD320.

Authors:  Hyo Jin Park; Ji-Yeon Kim; Kyung In Jung; Tae Jin Kim
Journal:  Immune Netw       Date:  2009-08-31       Impact factor: 6.303

9.  Role of CD45 signaling pathway in galactoxylomannan-induced T cell damage.

Authors:  Eva Pericolini; Elena Gabrielli; Giovanni Bistoni; Elio Cenci; Stefano Perito; Siu-Kei Chow; Francesca Riuzzi; Rosario Donato; Arturo Casadevall; Anna Vecchiarelli
Journal:  PLoS One       Date:  2010-09-14       Impact factor: 3.240

10.  N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death.

Authors:  Lesley A Earl; Shuguang Bi; Linda G Baum
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.